<DOC>
	<DOC>NCT00837967</DOC>
	<brief_summary>The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice a day (bid) in adult asthma patients.</brief_summary>
	<brief_title>Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition FEV1&gt; 70% of predicted normal value prebronchodilator Having a known or suspected allergy to study therapy (active drugs or additive) Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids within 3 months Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Symbicort Turbuhaler</keyword>
</DOC>